Strasbourg, France, 24 October 2023 – Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade has expanded the LipidBrick® Library with several new proprietary cationic lipids for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. Building forward from LipidBrick IM21.7c and off-the shelf in vivo-jetRNA®+ transfection reagent, these additional cationic lipids broaden the scope of LNP usage to treat various diseases.
LNPs have demonstrated high efficiency delivering RNA therapeutics in vivo, but they can be hard to modulate with challenges in the biodistribution profile. The entire LipidBrick Library IP (intellectual property) is based on a novel lipid structure protected by an independent patent owned by Polyplus. The LipidBrick Library is designed to enable a wider biodistribution and decrease accumulation in the liver to overcome traditional challenges in delivery.
“The LipidBrick product line has been designed to provide new options and solutions for developers of mRNA therapeutics to adapt the biodistribution to their therapeutic purposes. Through validation for LipidBrick IM21.7c, users have reported higher mRNA expression in the lungs and spleen while bypassing the liver, which was the goal,” said Claire Guéguen, Head of R&D Life Sciences at Polyplus. “We want to empower users to achieve simpler and more cost-effective processes. Working with the LipidBrick portfolio of modulating lipid nanoparticles (LNPs), we can do that by improving delivery of LNPs in vitro and in vivo and expanding the use of LNPs beyond the liver to screen and adapt the best suited lipid according to therapeutic applications.”
The LipidBrick Library is composed of several different cationic lipids, including IM21.7c, and is available for purchase online or via email. To learn more about the LipidBrick library, register for an upcoming webinar on October 25th where the team will discuss the characterization of a library of innovative imidazolium-based cationic lipids as key components of cationic LNPs (cLNPs).
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. The legacy nucleic acid delivery portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. In 2020, the company began focusing on upstream bioprocess economic optimization with the addition of custom plasmid vector design, GMP transfection reagent and plasmid manufacturing with an internalized supply chain designed to meet strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
Media Contact Information:
Alengo Nyamay’antu, PhD
Marketing & Communication team leader
Direct: +33 3 88 67 59 38